Can GLP-1 Drugs Protect the Kidneys in People With Diabetes?
Systematic review suggests GLP-1 receptor agonists may offer kidney-protective effects in type 2 diabetes, though evidence specifically focused on renal outcomes is limited.
Quick Facts
What This Study Found
GLP-1 receptor agonists show potential nephroprotective effects in type 2 diabetes, including improvements in eGFR and albuminuria, though dedicated renal outcome studies are limited.
Key Numbers
13 studies included (clinical trials and observational). Assessed eGFR and ACR outcomes. Quality assessed with validated bias risk tools. Overall trend toward nephroprotection but inconsistent across studies.
How They Did This
Systematic review of PubMed, Embase, Web of Science, and Cochrane Library for studies examining GLP-1 RA effects on kidney outcomes in type 2 diabetes patients.
Why This Research Matters
Kidney disease is a major complication of diabetes. If GLP-1 drugs protect the kidneys in addition to their metabolic benefits, it strengthens the case for their early and widespread use in diabetic patients.
The Bigger Picture
Adding kidney protection to the already impressive list of GLP-1 drug benefits (blood sugar, weight, heart, liver) would further establish these medications as comprehensive metabolic therapies.
What This Study Doesn't Tell Us
Few studies have been specifically designed to assess kidney outcomes as primary endpoints. Most kidney data comes from secondary analyses of cardiovascular or diabetes trials.
Questions This Raises
- ?Should dedicated kidney outcome trials be conducted for GLP-1 RAs?
- ?How do GLP-1 RA kidney effects compare to SGLT2 inhibitors, which have established nephroprotective evidence?
Trust & Context
- Key Stat:
- No prior review focused on kidneys While some studies examined kidney function, this is the first systematic review specifically focused on GLP-1 RA nephroprotective effects in diabetes
- Evidence Grade:
- Systematic review — methodologically sound but limited by the scarcity of dedicated renal outcome studies. Most evidence comes from secondary analyses.
- Study Age:
- Published in 2025, reflecting the growing interest in GLP-1 RA kidney effects.
- Original Title:
- Glucagon-like peptide-1 receptor agonists and its possible nephroprotective role: a systematic review.
- Published In:
- Minerva medica, 116(6), 454-460 (2025)
- Authors:
- Perencin, Alessandro, Ceolin, Chiara, Papa, Mario V, DI Marzio, Benedetta, Zanforlini, Bruno M, Devita, Maria, Curreri, Chiara, Gasparini, Giulia, Sergi, Giuseppe, DE Rui, Marina
- Database ID:
- RPEP-13022
Evidence Hierarchy
Analyzes all available research on a topic using a structured method.
What do these levels mean? →Frequently Asked Questions
Do GLP-1 drugs protect the kidneys?
The evidence is promising but not yet definitive. This systematic review found indications that GLP-1 drugs may slow kidney function decline in diabetic patients, but more dedicated kidney-focused studies are needed to confirm this.
Should I take a GLP-1 drug to protect my kidneys?
If you have type 2 diabetes, GLP-1 drugs offer multiple benefits including potential kidney protection. However, if kidney protection is a primary concern, discuss with your doctor whether an SGLT2 inhibitor — which has stronger renal evidence — might be appropriate.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13022APA
Perencin, Alessandro; Ceolin, Chiara; Papa, Mario V; DI Marzio, Benedetta; Zanforlini, Bruno M; Devita, Maria; Curreri, Chiara; Gasparini, Giulia; Sergi, Giuseppe; DE Rui, Marina. (2025). Glucagon-like peptide-1 receptor agonists and its possible nephroprotective role: a systematic review.. Minerva medica, 116(6), 454-460. https://doi.org/10.23736/S0026-4806.25.09709-5
MLA
Perencin, Alessandro, et al. "Glucagon-like peptide-1 receptor agonists and its possible nephroprotective role: a systematic review.." Minerva medica, 2025. https://doi.org/10.23736/S0026-4806.25.09709-5
RethinkPeptides
RethinkPeptides Research Database. "Glucagon-like peptide-1 receptor agonists and its possible n..." RPEP-13022. Retrieved from https://rethinkpeptides.com/research/perencin-2025-glucagonlike-peptide1-receptor-agonists
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.